{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362544420824671232.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/s0305-7372(98)90050-0"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0305737298900500?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0305737298900500?httpAccept=text/plain"}},{"identifier":{"@type":"NAID","@value":"30015244890"}}],"dc:title":[{"@value":"The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382544420824671233","@type":"Researcher","foaf:name":[{"@value":"M.J.A. de Jonge"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544420824671232","@type":"Researcher","foaf:name":[{"@value":"A. Sparreboom"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544420824671234","@type":"Researcher","foaf:name":[{"@value":"J. Verweij"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03057372"}],"prism:publicationName":[{"@value":"Cancer Treatment Reviews"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"1998-06","prism:volume":"24","prism:number":"3","prism:startingPage":"205","prism:endingPage":"220"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0305737298900500?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0305737298900500?httpAccept=text/plain"}],"createdAt":"2004-06-02","modifiedAt":"2019-02-07","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390282681104227712","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacologically Active Metabolites of Currently Marketed Drugs: Potential Resources for New Drug Discovery and Development"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291224979772672","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Double cancer (Iung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0305-7372(98)90050-0"},{"@type":"CIA","@value":"30015244890"},{"@type":"CROSSREF","@value":"10.1248/yakushi.130.1325_references_DOI_1V8RGR8R5LCGOaiM5D5ySCGCCVH"}]}